Načítá se...

Differential Healing After Sirolimus, Paclitaxel and Bare Metal Stent Placement in Combination with PPARγ Agonists: Requirement for mTOR/Akt2 in PPARγ Activation

RATIONALE: Sirolimus- (SES) and paclitaxel-eluting coronary stents (PES) are used to reduce restenosis, but have different sites of action. The molecular targets of sirolimus (SRL) overlap with those of the PPARγ agonist, rosiglitazone (RSG), but the consequence of this interaction on endothelializa...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Circ Res
Hlavní autoři: Finn, Aloke V., John, Michael, Nakazawa, Gaku, Polavarapu, Rohini, Karmali, Vinit, Xu, Xin, Cheng, Qi, Davis, Talina, Raghunathan, Chitra, Acampado, Eduardo, Ezell, Tucker, Lajoie, Scott, Eppihimer, Michael, Kolodgie, Frank D., Virmani, Renu, Gold, Herman Kalman
Médium: Artigo
Jazyk:Inglês
Vydáno: 2009
Témata:
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4492118/
https://ncbi.nlm.nih.gov/pubmed/19797172
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/CIRCRESAHA.109.200519
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!